Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma

Respiratory Medicine

Volumn 94, Issue 7, 2000, Pages 724-732

  Lundback B ^a   Jenkins, C ^b   Price, M J ^c   Thwaites, R M A ^c  

^a NATIONAL INSTITUTE FOR WORKING LIFE   (Sweden)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Asthma; Budesonide; Cost effectiveness analysis; Salmeterol fluticasone propionate

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SWEDEN; SYMPTOM;

EID: 0343022310     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2000.0876     Document Type: Article

References (37)

1. Smith D H, Malone D C, Lawson K, Okamoto L J, Battista C, Saunders W B. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 156:1997;787-793.
2. Jacobsson L, Lindgren B. Asthma: the cost to society [In Swedish]. Studies in Health Economics. 8:1995;University of Lund.
3. Donahue J G, Weiss S, Livingston J M, Goetsch M A, Greineder D K, Platt R. Inhaled steroids and the risk of hospitalisation for asthma. JAMA. 277:1997;887-891.
4. Balkrishnan R, Norwood G J, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther. 20:1998;1-14.
5. Rutten-van Molken M PMH, Van Doorslaer E KA, Jansen M CC, Van Essen-Zandvliet E E, Rutten F FH. Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator therapy in children with asthma. PharmacoEconomics. 4:1993;257-270.
6. Rutten-van Molken M PMH, Van Doorslaer E K, Jansen M C, Kerstjens H A, Rutten F F. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 151:1995;975-982.
7. Barnes N C, Marone G, Di Maria Gu, Visser S, Utama I, Payne S L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 6:1993;877-885.
8. Fabbri L, Burge P S, Croonenborgh L. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax. 48:1993;817-823.
9. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child. 69:1993;206-211.
10. -1) administered by pressurized inhaler. Respir Med. 87:1993;609-620.
11. Langdon C G, Capsey L J. Fluticasone propionate and budesonide in adult asthmatics: a comparison using dry-powder inhaler devices. Br J Clin Res. 5:1994;85-89.
12. Langdon C G, Thompson J. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered-dose inhalers in adults with mild-to-moderate asthma. Br J Clin Res. 5:1994;73-84.
13. Connolly A. A comparison of fluticasone propionate 100 μ g twice daily with budesonide 200 μ g twice daily via their respective powder devices in the treatment of mild asthma. Eur J Clin Res. 7:1995;15-29.
14. Katz Y, Lebas F X, Medley H V, Robson R. Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group. Clin Ther. 29:1998;424-437.
15. Adinoff A D, Schwartz H J, Rickard K A, Yancey S W, Swearingen B E. Salmeterol compared with current therapies in chronic asthma. J Fam Pract. 47:1998;278-284.
16. Kemp J, Wolfe J, Grady J. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clin Ther. 20:1998;270-282.
17. Vervloet D, Ekstrom T, Pela R. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med. 92:1998;836-842.
18. Weinstein S F, Pearlman D S, Bronsky E A. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Ann Allergy Asthma Immunol. 81:1998;51-58.
19. Wenzel S E, Lumry W, Manning M. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol. 80:1998;463-470.
20. Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 344:1994;219-224.
21. Woolcock A, Lundback B, Ringdal N, Jacques L A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 153:1996;1481-1488.
22. Pauwels R A, Löfdahl C G, Postma D S. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 337:1997;1405-1411.
23. Ind P W, Dal Negro R, Colman N, Fletcher C P, Browning D C, James M H. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms. Am J Respir Crit Care Med. 157:1998;416.
24. Condemi J J, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol. 82:1999;383-389.
25. Murray J J, Church N L, Anderson W H. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc. 20:1999;173-180.
26. Anderson F, Ståhl E, Barnes P J. The costs and effects of adding formoterol to budesonide - results from the FACET study. Am J Respir Crit Care Med. 159:1999;A762.
27. Ind P W, Cargill K, Thwaites R MA. Addition of salmeterol xinafoate to fluticasone propionate produces cost-effective asthma management. Am J Respir Crit Care Med. 159:1999;A636.
28. Chapman K R, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 μ g) administered via combination Diskus inhaler: as effective as when given via seperate Diskus inhalers. Can Respir J. 6:1999;45-51.
29. Gross G, Woodring A, Prillman B, House K, Shah T. Efficacy and safety of the salmeterol/fluticasone propionate (50/100 μ g) dry powder combination inhaler in patients with asthma. Eur Respir J. 12:1998;156.
30. Nathan R, Woodring A, Baitinger L. The salmeterol/fluticasone propionate Diskus combination decreases the incidence of exacerbations compared to treatment with salmeterol or fluticasone propionate alone. Eur Respir J. 14:1999;123s.
31. Shapiro G, Lumry W, Wolfe J. Combined salmeterol 50 μ g and fluticasone propionate 250 μ g in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med. 161:2000;527-534.
32. Jenkins C, Woolcock A J, Saarelainen P, Lundbäck B, James M H. Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthma. Respir Med. 94:2000;715-723.
33. Sculpher M J, Buxton M J. The episode-free day as a composite measure of effectiveness. An illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. PharmacoEconomics. 4:1993;345-352.
34. Kostnader per intagen patient, Stockholm, Landstingsförbundet Utgivningsår, 1995.
35. FASS, läkemedel i Sverige, förteckning över humanläkemendel Deltitel, 1998.
36. Briggs A H, Wonderling D E, Mooney C Z. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 6:1997;327-340.
37. Booth P C, Capsey L J, Langdon C G, Wells N EJ. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ. 8:1995;65-72.